Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03987204 · ClinicalTrials.gov registry record · Phase 1
Ivabradine for Rate Control in Permanent Atrial Fibrillation
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03987204: Completed Phase 1 study, sponsored by Yale University.
NCT03987204 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03987204, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Ivabradine may be useful as a rate controlling agent in atrial fibrillation without negative effects on hemodynamics and inotropy. The objective in this proof of concept study is to investigate the hypothesis that ivabradine will slow the ventricular response in patients with permanent atrial fibrillation and previously-implanted pacemakers.
Primary Outcome
Average ventricular heart rate derived using pacemaker interrogation over 2 weeks
Interventions
- DRUG Ivabradine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-06-15 |
| Est. Completion | 2019-09-17 |
| Phase | Phase 1 |
What the finished NCT03987204 record still lists
NCT03987204 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Ivabradine is the first listed.
NCT03987204 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03987204 about?
NCT03987204 is a clinical study titled "Ivabradine for Rate Control in Permanent Atrial Fibrillation". Ivabradine may be useful as a rate controlling agent in atrial fibrillation without negative effects on hemodynamics and inotropy. The objective in this proof of concept study is to investigate the hypothesis that ivabradine will slow the ventricular response in patients with permanent atrial fibril...
What is the current status of trial NCT03987204?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2019-06-15. Estimated completion is 2019-09-17.
What interventions are being tested in trial NCT03987204?
The interventions under investigation include: Ivabradine (DRUG).
Who is sponsoring clinical trial NCT03987204?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03987204's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI